UNSPSC 51382001: Bufexamac

This classification denotes a non-steroidal anti-inflammatory agent with the molecular formula C12H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4T3C38J78L, chemically known as benzeneacetamide, 4-butoxy-n-hydroxy- (9ci) but generally known as bufexamac, which bears US NIH Compound Identifier 2466. European Medicines Agency schedules Bufexamac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05961MIG.

UNSPSC 51382001 Bufexamac is a Commodity code, but the recent state and local procurement activity tagged under it does not align with the code's nominal scope — bufexamac is a topical anti-inflammatory compound, yet the opportunities posted show purchasing of naloxone (an opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements. The mismatch suggests either a data-tagging error in the source records or that the code is being used as a catch-all for pharmaceutical and medical product procurement beyond its intended definition. Across the three opportunities, issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local governments including Oregon). The scope of actual work being solicited includes direct purchase of finished pharmaceutical products for community health support, exploratory market intelligence on direct-to-manufacturer pharmacy programs, and framework agreements with manufacturers to supply generic drugs and OTC items through established pharmaceutical wholesalers.

Activity concentrates in the South and Midwest, with named opportunities from Florida, Texas, and Minnesota. The most recent solicitation is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program — this is exploratory intelligence-gathering rather than a formal competitive bid. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, due March 26, 2026, requiring vendors to supply through three authorized wholesalers with a July 1, 2026 contract effective date and pricing weighted 75 percent on competitiveness. No explicit set-asides or disadvantaged-enterprise restrictions appear in the solicitation materials, though vendors must meet standard compliance certifications including cGMP, DSCSA, E-Verify, and insurance requirements.